Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Chiral Amine. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN114349648A details a one-step ruthenium-catalyzed reductive amination for high-purity chiral amines, offering significant cost reduction and supply chain reliability for pharmaceutical manufacturing.
Patent CN103224963B reveals marine strain catalysis for high-purity chiral amines. Offers significant cost reduction and supply chain reliability for pharmaceutical intermediates manufacturing.
Patent CN112142784B details iridium-catalyzed asymmetric hydrogenation yielding high-purity chiral amines with >99% ee, enabling cost-effective API manufacturing.
Patent CN119614533B reveals thermostable enzyme mutants improving R-chiral amine synthesis efficiency and supply chain stability for pharmaceutical intermediates.
Patent CN110577941B reveals mutated enzymes for high-purity chiral amine synthesis, offering cost reduction in pharmaceutical intermediate manufacturing via biocatalysis.
Patent CN110577941B details mutated amine dehydrogenase for asymmetric reductive amination, offering high optical purity and scalable biocatalysis for pharmaceutical intermediates.
Patent CN110734378B reveals a mild Ni-catalyzed method for high-ee chiral allylamines. Discover cost-effective manufacturing and scalable supply chain solutions.
Patent CN110914417B reveals high-activity transaminase for chiral amine synthesis, offering cost reduction and supply chain reliability for pharmaceutical intermediates.
Patent CN104418775B details palladium-catalyzed asymmetric hydrogenolysis for high-purity chiral amine production offering significant supply chain and cost advantages.
Novel transaminase mutants for chiral amine production. Enhanced stability at 55°C and pH 10. Cost-effective biocatalysis for pharma intermediates.
Patent CN112010910B details a novel iridium-catalyzed synthesis of chiral ferrocene homoallylamines, offering high yields and enantioselectivity for cost-effective pharmaceutical intermediate manufacturing.
Novel iridium-catalyzed synthesis offers high enantioselectivity for pharmaceutical intermediates. Enhances supply chain reliability and reduces manufacturing costs significantly.
High-purity chiral amine intermediate for levopraziquantel. Enzymatic process ensures cost reduction and supply reliability for pharmaceutical manufacturing.
Novel ferrocene-derived iridium catalyst enables high-efficiency chiral amine synthesis with reduced processing costs for reliable agrochemical intermediate supply chains.
Patent CN1538950A details a mild transfer hydrogenation method for amine synthesis using Ru/Rh catalysts, offering cost reduction in API manufacturing and high optical purity.
Novel 3-step synthesis for chiral 2-fluoromethyl phenyl ethylamine. High purity, scalable route for pharmaceutical intermediates. Cost-effective production.
Patent CN101778815B reveals a streamlined synthesis for chiral N-halopropyl amino acids, offering cost reduction in API manufacturing and superior supply chain reliability.
Patent CN102627590A details a mild route to chiral alpha-tribromomethyl amines. Offers high optical purity and scalable conditions for API intermediates.
Patent CN102076634A details enantioselective hydrogenation of N-H imines. Discover cost-effective routes for high-purity pharmaceutical intermediates without protection steps.
Novel BCl3 catalyzed route improves yield and safety for SGLT2 inhibitor manufacturing supply chain reliability and cost efficiency significantly for global buyers.